Research Activity
NuCana’s Chemotherapy Replacement Fails to Improve Survival in Phase II Trial
NuCana, chemotherapy replacement, Phase II trial, progression-free survival, colorectal cancer, NUC-3373
Future-Proofing Healthcare: Inclusive and Protective Patient Strategies
future-proofing, inclusive healthcare, patient-centered care, digital patient experience, data linkage, clinical trials, health and safety programs
Novartis Expands Leqvio’s Potential After Successful Phase III Study Demonstrates Significant Cholesterol Reduction
Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
Genentech Announces 93 Layoffs in California Amid Restructuring Efforts
Genentech layoffs, California job cuts, biotech industry, cancer immunology research, restructuring efforts
Rafael Holdings and Cyclo Therapeutics Merge to Accelerate Development of Niemann-Pick Disease Type C1 Treatment
Rafael Holdings, Cyclo Therapeutics, merger, Niemann-Pick Disease Type C1, Trappsol Cyclo, clinical trial, pharmaceutical development
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
Walgreens and BARDA Collaborate on $100M Decentralized Clinical Trials Initiative
Walgreens, BARDA, Decentralized Clinical Trials, $100M Partnership, Healthcare Research
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety
FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research
MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.